Tilborg Anaëlle, Jacquemin Denis, Norberg Bernadette, Perpète Eric, Michaux Catherine, Wouters Johan
UCPTS, Faculté des Sciences, Rue de Bruxelles 61, Namur B-5000, Belgium.
Acta Crystallogr B. 2011 Dec;67(Pt 6):499-507. doi: 10.1107/S0108768111045113. Epub 2011 Nov 17.
Pharmaceutical compounds are mostly developed as solid dosage forms containing a single-crystal form. It means that the selection of a particular crystal state for a given molecule is an important step for further clinical outlooks. In this context, piracetam, a pharmaceutical molecule known since the sixties for its nootropic properties, is considered in the present work. This molecule is analyzed using several experimental and theoretical approaches. First, the conformational space of the molecule has been systematically explored by performing a quantum mechanics scan of the two most relevant dihedral angles of the lateral chain. The predicted stable conformations have been compared to all the reported experimental geometries retrieved from the Cambridge Structural Database (CSD) covering polymorphs and cocrystals structures. In parallel, different batches of powders have been recrystallized. Under specific conditions, single crystals of polymorph (III) of piracetam have been obtained, an outcome confirmed by crystallographic analysis.
药物化合物大多被开发为含有单晶形式的固体剂型。这意味着为给定分子选择特定的晶体状态是进一步临床前景的重要一步。在这种背景下,本文研究了自六十年代以来就因其益智特性而闻名的药物分子吡拉西坦。使用几种实验和理论方法对该分子进行了分析。首先,通过对侧链两个最相关的二面角进行量子力学扫描,系统地探索了该分子的构象空间。将预测的稳定构象与从剑桥结构数据库(CSD)检索到的所有报道的实验几何结构进行了比较,这些结构涵盖了多晶型物和共晶体结构。同时,对不同批次的粉末进行了重结晶。在特定条件下,获得了吡拉西坦多晶型物(III)的单晶,晶体学分析证实了这一结果。